Potential role of immune modulation in the effective long-term control of HIV-1 infection

G. Paolo Rizzardi, A. Lazzarin, G. Pantaleo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Recent advances in HIV-1 pathogenesis, and in defining virological and immunological responses to highly active antiretroviral therapy (HAART), along with the identification of the numerous drawbacks of HAART, have clearly demonstrated that the eradication of the virus is not a feasible therapeutic goal, and that there is an urgent need to develop other approaches to fight HIV-1 infection. Novel therapeutic approaches of immune modulation have recently been evaluated in pilot clinical trials. First, treating primary HIV-1 infection with cyclosporin A (CsA) coupled with HAART to target massive immune activation extends the benefits achieved with HAART during primary HIV-1 infection and might contribute to the establishment of a more favourable immunological set-point affecting the ultimate pattern and rate of disease progression. Second, treating chronic HIV-1 infection in patients with long-term suppression of virus replication induced by HAART, with the addition of mycophenolate mofetil (MMF) reduces the pool of activated CD4+ T lymphocytes able to support productive HIV-1 infection, and might have an indirect impact on the pool of resting, latently infected CD4+ T cells, contributing to its depletion in vivo. The important question is clearly whether these results will have an impact on the clinical management of patients with HIV-1 infection, determining the precise therapeutic function of drugs like CsA and MMF, thus investigating the effects of these drugs on residual viral replication and the decay of the latent reservoir, on long-term immunogical benefit, and, ultimately, on clinical benefit.

Original languageEnglish
Pages (from-to)83-90
Number of pages8
JournalJournal of Biological Regulators and Homeostatic Agents
Volume16
Issue number1
Publication statusPublished - 2002

Fingerprint

Human immunodeficiency virus 1
HIV Infections
HIV-1
Highly Active Antiretroviral Therapy
therapeutics
infection
Mycophenolic Acid
cyclosporine
Cyclosporine
virus replication
T-lymphocytes
T-Lymphocytes
drugs
Virus Replication
Pharmaceutical Preparations
Disease Progression
disease course
Therapeutics
clinical trials
Clinical Trials

Keywords

  • CsA
  • HAART
  • HIV
  • Immune-based strategies
  • MMF
  • Primary and chronic infection

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Physiology (medical)
  • Medicine (miscellaneous)
  • Physiology
  • Agricultural and Biological Sciences(all)

Cite this

Potential role of immune modulation in the effective long-term control of HIV-1 infection. / Rizzardi, G. Paolo; Lazzarin, A.; Pantaleo, G.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 16, No. 1, 2002, p. 83-90.

Research output: Contribution to journalArticle

@article{8cc93c58a7d247b586debfeb29f9e5d0,
title = "Potential role of immune modulation in the effective long-term control of HIV-1 infection",
abstract = "Recent advances in HIV-1 pathogenesis, and in defining virological and immunological responses to highly active antiretroviral therapy (HAART), along with the identification of the numerous drawbacks of HAART, have clearly demonstrated that the eradication of the virus is not a feasible therapeutic goal, and that there is an urgent need to develop other approaches to fight HIV-1 infection. Novel therapeutic approaches of immune modulation have recently been evaluated in pilot clinical trials. First, treating primary HIV-1 infection with cyclosporin A (CsA) coupled with HAART to target massive immune activation extends the benefits achieved with HAART during primary HIV-1 infection and might contribute to the establishment of a more favourable immunological set-point affecting the ultimate pattern and rate of disease progression. Second, treating chronic HIV-1 infection in patients with long-term suppression of virus replication induced by HAART, with the addition of mycophenolate mofetil (MMF) reduces the pool of activated CD4+ T lymphocytes able to support productive HIV-1 infection, and might have an indirect impact on the pool of resting, latently infected CD4+ T cells, contributing to its depletion in vivo. The important question is clearly whether these results will have an impact on the clinical management of patients with HIV-1 infection, determining the precise therapeutic function of drugs like CsA and MMF, thus investigating the effects of these drugs on residual viral replication and the decay of the latent reservoir, on long-term immunogical benefit, and, ultimately, on clinical benefit.",
keywords = "CsA, HAART, HIV, Immune-based strategies, MMF, Primary and chronic infection",
author = "Rizzardi, {G. Paolo} and A. Lazzarin and G. Pantaleo",
year = "2002",
language = "English",
volume = "16",
pages = "83--90",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "1",

}

TY - JOUR

T1 - Potential role of immune modulation in the effective long-term control of HIV-1 infection

AU - Rizzardi, G. Paolo

AU - Lazzarin, A.

AU - Pantaleo, G.

PY - 2002

Y1 - 2002

N2 - Recent advances in HIV-1 pathogenesis, and in defining virological and immunological responses to highly active antiretroviral therapy (HAART), along with the identification of the numerous drawbacks of HAART, have clearly demonstrated that the eradication of the virus is not a feasible therapeutic goal, and that there is an urgent need to develop other approaches to fight HIV-1 infection. Novel therapeutic approaches of immune modulation have recently been evaluated in pilot clinical trials. First, treating primary HIV-1 infection with cyclosporin A (CsA) coupled with HAART to target massive immune activation extends the benefits achieved with HAART during primary HIV-1 infection and might contribute to the establishment of a more favourable immunological set-point affecting the ultimate pattern and rate of disease progression. Second, treating chronic HIV-1 infection in patients with long-term suppression of virus replication induced by HAART, with the addition of mycophenolate mofetil (MMF) reduces the pool of activated CD4+ T lymphocytes able to support productive HIV-1 infection, and might have an indirect impact on the pool of resting, latently infected CD4+ T cells, contributing to its depletion in vivo. The important question is clearly whether these results will have an impact on the clinical management of patients with HIV-1 infection, determining the precise therapeutic function of drugs like CsA and MMF, thus investigating the effects of these drugs on residual viral replication and the decay of the latent reservoir, on long-term immunogical benefit, and, ultimately, on clinical benefit.

AB - Recent advances in HIV-1 pathogenesis, and in defining virological and immunological responses to highly active antiretroviral therapy (HAART), along with the identification of the numerous drawbacks of HAART, have clearly demonstrated that the eradication of the virus is not a feasible therapeutic goal, and that there is an urgent need to develop other approaches to fight HIV-1 infection. Novel therapeutic approaches of immune modulation have recently been evaluated in pilot clinical trials. First, treating primary HIV-1 infection with cyclosporin A (CsA) coupled with HAART to target massive immune activation extends the benefits achieved with HAART during primary HIV-1 infection and might contribute to the establishment of a more favourable immunological set-point affecting the ultimate pattern and rate of disease progression. Second, treating chronic HIV-1 infection in patients with long-term suppression of virus replication induced by HAART, with the addition of mycophenolate mofetil (MMF) reduces the pool of activated CD4+ T lymphocytes able to support productive HIV-1 infection, and might have an indirect impact on the pool of resting, latently infected CD4+ T cells, contributing to its depletion in vivo. The important question is clearly whether these results will have an impact on the clinical management of patients with HIV-1 infection, determining the precise therapeutic function of drugs like CsA and MMF, thus investigating the effects of these drugs on residual viral replication and the decay of the latent reservoir, on long-term immunogical benefit, and, ultimately, on clinical benefit.

KW - CsA

KW - HAART

KW - HIV

KW - Immune-based strategies

KW - MMF

KW - Primary and chronic infection

UR - http://www.scopus.com/inward/record.url?scp=0036255472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036255472&partnerID=8YFLogxK

M3 - Article

C2 - 12003181

AN - SCOPUS:0036255472

VL - 16

SP - 83

EP - 90

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 1

ER -